Tech Company Financing Transactions
Aptimmune Biologics Funding Round
Private investors participated in a $2.2 million venture round for Aptimmune Biologics. The round was recorded on 7/12/2017.
Transaction Overview
Company Name
Announced On
7/12/2017
Transaction Type
Venture Equity
Amount
$2,200,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 3 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1005 N. Warson Rd.
St. Louis, MS 63132
USA
St. Louis, MS 63132
USA
Phone
Website
Email Address
Not Recorded
Overview
Aptimmune Biologics specializes in developing revolutionary mucosal vaccines that provide unsurpassed efficacy against the viral diseases most costly to the swine industry. We focus solely on swine vaccines and the prevention of two major diseases -- Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and influenza.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Robert Nordgren
Chief Executive Officer
Heather Bessoff
Chief Scientific Officer
Federico Zuckermann
VP - Marketing
Andrew Smythe
Browse more venture capital transactions:
Prev: 7/12/2017: Evelo Biosciences venture capital transaction
Next: 7/12/2017: Movile venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs